Epithelial cancer evaluation using beta defensin
US10816549B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 15, 2016 |
| Grant date | Oct 27, 2020 |
| Priority date | — |
| Expiry date | Dec 15, 2036 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/4721
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A method of detecting epithelial cancer is described that includes the steps of: (a) determining the level of beta defensin 3 (BD-3) and beta defensin 2 (BD-2) in a suspect sample obtained from a subject; (b) comparing the level of BD-3 to BD-2 determined in the suspect sample to obtain a suspect BD-3/BD-2 ratio, (c) comparing the suspect BD-3/BD-2 ratio to a healthy BD-3/BD-2 ratio to obtain a diagnostic BD-3/BD-2 ratio; and (d) characterizing the subject as having epithelial cancer if the diagnostic BD-3/BD-2 ratio is greater than 1. A microfluidic device for detecting epithelial cancer using the diagnostic BD-3/BD-2 ratio is also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.